Though a rival’s Alzheimer’s drug reached the market first, the CEO of Eli Lilly spoke confidently Tuesday about its amyloid-clearing product’s potential to take on Biogen’s recently launched Aduhelm.
Speaking at STAT’s Breakthrough Science Summit, CEO David Ricks said Lilly last month asked the Food and Drug Administration to expedite approval of its drug donanemab for “business reasons, competitive reasons, but more importantly, patient reasons.”
Before Aduhelm’s approval, but aware of its pending decision date with the FDA, Lilly announced encouraging results in March from its Phase 2 trial of donanemab in about 100 people. The drug was the first amyloid-plaque-clearing drug to slow the cognitive decline of patients who took it compared to those who got a placebo — the study’s primary endpoint.
About the Author Reprints
